C-KIT expression in primary and metastatic merkel cell carcinoma

American Journal of Dermatopathology

Volumn 26, Issue 6, 2004, Pages 458-462

  Feinmesser, Meora ^a   Halpern, Marisa ^a   Kaganovsky, Ella ^a   Brenner, Baruch ^a   Fenig, Eyal ^a   Hodak, Emmilia ^a   Sulkes, Jaqueline ^a,b   Okon, Elimelech ^a  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

c kit; Merkel cell carcinoma; Tyrosine kinase inhibitors

Indexed keywords

ANTIBODY; FORMALDEHYDE; PARAFFIN; STEM CELL FACTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; MERKEL CELL TUMOR; MITOSIS RATE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS;

AGED; AGED, 80 AND OVER; CARCINOMA, MERKEL CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-KIT; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 11444262478     PISSN: 01931091     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000372-200412000-00003     Document Type: Article

References (23)

1. Boyle F, Pendlebury S, Bell D. Further insights into the natural history and management of primary cutaneous neuroendocrine (Merkel cell) carcinoma. Int J Radiat Oncol Biol Phys. 1995;31:315-323.
2. Hitchcock CL, Bland KI, Laney RG, et al. Neuroendocrine (Merkel cell) carcinoma of the skin. Ann Surg. 1988;207:201-207.
3. Meeuwissen JA, Bourne RG, Kearsley JH. The importance of post-operative radiation therapy in the treatment of Merkel cell carcinoma. Int J Radiat Oncol Biol Phys. 1995;31:325-331.
4. Fenig E, Lurie H, Sulkes A. The use of cycloheximide, methotrexate and 5-fluorouracil in the treatment of Merkel cell carcinoma. Am J Clin Oncol 1993;16:54-57.
5. Su LD, Fullen DR, Lowe L, et al. CD117 (KIT receptor) expression in Merkel cell carcinoma. Am J Dermatopathol. 2002;24:289-293.
6. Strong S, Shalders K, Carr R, et al. KIT receptor (CD117) expression in Merkel cell carcinoma. Br J Dermatol. 2004;150:384-385.
7. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative, Cancer Res. 1996;56:100-104.
8. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566.
9. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI 571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000;295:139-145.
10. Heinrich MC, Griffith DJ, Druker BJ, et al. Inhibition of c-kit receptor tyrosine activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000;96:925-932.
11. Tuveson DT, Fletcher CDM, Singer S, et al. STI 571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: Biological and clinical implications. Oncogene. 2001;20:5054-5058.
12. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI 571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344:1052-1056.
13. Demetri GD. Targeting c-kit mutations in solid tumors: Scientific rationale and novel therapeutic options. Semin Oncol. 2001;28(Suppl 17):19-26.
14. Kantargian HM, Tapaz M. Imatinib mesylate: Clinical results in Philadelphia chromosome-positive leukemias. Semin Oncol. 2001;28(Suppl 17):9-18.
15. Tsuura Y, Hiraki H, Watanabe K, et al. Preferential localization of c-kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma and seminoma/dysgerminoma in humans: immunohistochemical study on formalin-fixed, paraffin-embedded tissues. Virchows Arch. 1994;424:135-141.
16. Hibi K, Takahashi T, Sekido Y, et al. Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene. 1991;6:2291-2296.
17. Krystal GW, Honsawek S, Litz J, et al. The selective tyrosine kinase inhibitor STI 571 inhibits small cell lung cancer growth. Clin Cancer Res. 2000;6:3319-3326.
18. Krystal GW, Honsawek S, Kiewlich D, et al. Indolinone tyrosine kinase inhibitors block kit activation and growth of small cell lung cancer cells. Cancer Res. 2001;61:3660-3668.
19. Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 2001;61:8118-8121.
20. Heinrich MC, Rubin BP, Longley BJ, et al. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol. 2002;33:484-495.
21. Grichnik JM, Ali WN, Burch JA, et al. KIT expression reveals a population of precursor melanocytes in human skin. J Invest Dermatol. 1996;106:967-971.
22. Skelton HG, Smith KJ, Hitchcock CL, et al. Merkel cell carcinoma: analysis of clinical, histologic and immunohistologic features of 132 cases with relation to survival. J Am Acad Dermatol. 1997;37:734-739.
23. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, et al. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol. 1998;11:728-734.